Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
BECKER D, IYENGAR A, PUNEKAR S, NG J, ZAMAN A, LOEB S, BECKER K, MAKAROV D. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. Anticancer Research 2019, 39: 2467-2473. PMID: 31092441, DOI: 10.21873/anticanres.13366.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAbi/enzaCastration-resistant prostate cancerPSA progressionEnd of lifeProstate cancerVeterans AffairsOlder patientsBlack patientsClinical benefitClinical endpointsHospice servicesNational guidelinesPatientsEnza treatmentAdditional studiesProgressionENZAAbirateroneRegression analysisCancerTreatmentABIEnzalutamideEndpoint